

ADDENDUM

STATE: Washington	BUSINESS UNIT(S): Coordinated Care
PRODUCT TYPE: Medicaid	P&P NAME: 72-Hour Supply of Medication
P&P NUMBER: CC.PHARM.CS.01	REGULATOR MOST RECENT APPROVAL DATE(S): N/A

BACKGROUND:

To provide contractually required information that varies from the Centene Corporate policy/procedure.

DEFINITIONS:

Emergency Fill- “Emergency Fill” means the dispensing of a prescribed medication to a Member by a licensed pharmacist who has used his or her professional judgment in identifying that the Member has an Emergency Medical Condition for which lack of immediate access to pharmaceutical treatment would result in, (a) placing the health of the individual or, with respect to a pregnant woman, the health of the woman or her unborn child, in serious jeopardy; (b) serious impairment to bodily functions; or (c) serious dysfunction of any bodily organ or part.

Durable Medical Equipment- “Durable Medical Equipment” means medical equipment and appliances, and medical supplies as defined in WAC 182-543-1000. Medical equipment and appliances are primarily and customarily used to serve a medical purpose, generally are not useful for a person in the absence of illness or injury, can withstand repeated use, can be reusable or removable, and are suitable for use in any setting where normal life activities take place.

Non-Contracted Drug- “Non-Contracted Drug” means a drug that HCA excludes from the premium payments for the AH Family Adult, AH Family Child, Apple Health State Children’s Health Insurance Program (SCHIP), Apple Health Blind Disabled (AHBD), Apple Health Community Options Program Entry System (COPEs), Developmental Disability Administration (DDA) and Apple Health Adult Coverage (AHAC) populations when not administered in an inpatient setting.

SECTION ONE:

Procedure

Statement of unique item/requirement

- Coordinated Care of Washington, Inc., (Coordinated Care) authorizes pharmacies to provide up to a 30-day supply of medication in situations where an emergency fill is needed. Coordinated Care must be contacted within 7 days or before filling the medication again (whichever is sooner).
- Coordinated Care authorizes pharmacies to provide up to a 30-day supply of medication in situations when a delay in authorization would interrupt a drug therapy that must be continuous or when the delay would pose a threat to the Member’s health and safety. The drug supply must be sufficient to bridge the time until an authorization determination is made.

Exclusions

Statement of unique item/requirement

5. Medication for professionally administered drugs, Durable Medical Equipment (DME), and non-contracted drugs are exclusions to the policy. For the list of non-contracted drugs, refer to <https://www.hca.wa.gov/assets/billers-and-providers/drugs-excluded-from-MCO-responsibility.xlsx>

Reference: Sections 6.6.1.5, 11.5.6– Washington Apple Health Integrated Managed Care (IMC) Contract

SECTION TWO:

Process 3

Statement of unique item/requirement

3. Coordinated Care will cover emergency fills without authorization when dispensed by a contracted pharmacy. The dispensing pharmacist will be allowed to dispense up to a 30-day supply of medication.

SECTION THREE:

Other

Statement of unique item/requirement

For **over-the-counter (OTC) contraceptives**, the dispensing pharmacist may use their professional judgment to meet a member’s urgent medical need, such as a medication that needs to be taken within a specific timeframe, by issuing an emergency fill to the member. Coordinated Care guarantees payment on claims meeting the emergency fill policy even in circumstances where OTC birth control products do not have federal rebate.

REVISION LOG

REVISION:	DATE:
Addendum created	01.23
Annual Review- Updated Reference Sections	01.24
Added a section pertaining to dispensing of OTC contraceptives as an emergency fill (per HCA Issue #42699)	10.24
Updated policy number	11/14/2025
Minor grammatical updates made Added language that pharmacies are authorized to provide up to a 30-day supply of medication in situations when a delay in authorization would interrupt a drug therapy that must be continuous or when the delay would pose a threat to the Member’s health and safety Updated Reference Section numbering	11.25